AstraZeneca's COVID-19 vaccine adverse event has NIH 'very concerned'

Leaders at the National Institutes of Health (NIH) are “very concerned” about the adverse event that led AstraZeneca to pause its COVID-19 vaccine clinical trial, according to the intramural clinical director at one of its divisions.